A relative increase in circulating platelets following chemoradiation predicts for poor survival of patients with glioblastoma
Open Access
- 12 October 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (52) , 90488-90495
Abstract
Background: Thrombocytosis is triggered by and promotes tumor growth. The relationship between the change in circulating platelets after chemoradiation therapy (CRT) or adjuvant temozolomide (TMZ) and survival in glioblastoma remains unclear. We hypothesized that an increase in platelets after these treatments would be predictive of a shorter survival.Keywords
This publication has 28 references indexed in Scilit:
- Platelets Promote Tumor Growth and Metastasis via Direct Interaction between Aggrus/Podoplanin and CLEC-2PLOS ONE, 2013
- Platelet CLEC-2 and podoplanin in cancer metastasisThrombosis Research, 2012
- Cancer immunotherapy via dendritic cellsNature Reviews Cancer, 2012
- Modulation of Natural Killer Cell Anti-Tumor Reactivity by PlateletsJournal of Innate Immunity, 2011
- Platelet-Derived Transforming Growth Factor-β Down-Regulates NKG2D Thereby Inhibiting Natural Killer Cell Antitumor ReactivityCancer Research, 2009
- Where is VEGF in the body? A meta-analysis of VEGF distribution in cancerBritish Journal of Cancer, 2007
- Preoperative thrombocytosis predicts poor survival in patients with glioblastomaNeuro-Oncology, 2007
- Differential role of platelet granular mediators in angiogenesisCardiovascular Research, 2004
- Platelets mediate tumor cell adhesion to the subendothelium under flow conditions: Involvement of platelet GPIIb-IIIa and tumor cell ?v integrinsInternational Journal of Cancer, 1997
- Inhibition of Human Natural Killer Cell Activity by Platelet‐Derived Growth Factor (PDGF)Scandinavian Journal of Immunology, 1991